Merck Sharp + Dohme B.v.

Jazz Pharmaceuticals Research UK Limited

Paul Stuart Hinchliffe

Wesley Peter Blackaby

Andrew Sharpe

Cornelis Marius Timmers

James Daniel Osborne

Martin De Kort

Mark Enthoven

Saskia Verkaik

Christian Bernard Matthijs Poulie

Cristian Bernard Matthijs Poulie

Alan James Silcock

Christian Bernard Poulie

Martin Dekort

Antoine Millet

Karen Ka-Yen Tse

The invention relates to FSH receptor antagonist according to general formula I or a pharmaceutically acceptable salt thereof and to a pharmaceutical composition containing the same. The compounds can be used for the treatment and prevention of endometriosis, for the treatment and prevention of pre-menopausal and peri-menopausal hormone-dependent breast cancer, for contraception, and for the treatment of uterine fibroids and other menstrual-related disorders.

FSH receptor antagonists

The invention relates to FSH receptor antagonist according to general formula (I) or a pharmaceutically acceptable salt thereof and to a pharmaceutical composition containing the same. The compounds can be used for the treatment and prevention of endometriosis, for the treatment and prevention of pre-menopausal and peri-menopausal hormone-dependent breast cancer, for contraception, and for the treatment of uterine fibroids and other menstrual-related disorders. 

The invention relates to FSH receptor antagonist according to general formula I or a pharmaceutically acceptable salt thereof and to a pharmaceutical composition containing the same. The compounds can be used for the treatment and prevention of endometriosis, for the treatment and prevention of pre-menopausal and peri-menopausal hormone-dependent breast cancer, for contraception, and for the treatment of uterine fibroids and other menstrual-related disorders. 

Growing community of inventors

Saffron, United Kingdom

Paul Stuart Hinchliffe